Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

• Main Authors: Zhenwei Yu (Author), Xiaofen Liu (Author), Xiaoxing Du (Author), Huiying Chen (Author), Feng Zhao (Author), Zhihui Zhou (Author), Yu Wang (Author), Yang Zheng (Author), Phillip J. Bergen (Author), Xi Li (Author), Renhua Sun (Author), Li Fang (Author), Wanzhen Li (Author), Yaxin Fan (Author), Hailan Wu (Author), Beining Guo (Author), Jian Li (Author), Yunsong Yu (Author), Jing Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Polymyxin B is a last-line therapy for carbapenem-resistant microorganisms. However, a lack of clinical pharmacokinetic/pharmacodynamic (PK/PD) data has substantially hindered dose optimization and breakpoint setting.Methods: A prospective, multi-center clinical trial was undertaken wi...